ArticleNeoplasia (New York, N.Y.)2015

IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.

Xiaolin Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.